Evidence map›Paper›PMID 39711783›Full record

ArticleFrontiers in cellular and infection microbiology2024

Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant

Yitan Li, Xiandi Chen, Yingyi Guo, Yingzhuo Lin, Xiaohu Wang, Guohua He, Mingzhen Wang, Jianbo Xu, Mingdong Song, Xixi Tan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Tandem amplification of theMicrobiology spectrum · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. CombatingFrontiers in cellular and infection microbiology · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yitan Li *Key Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Xiandi Chen *Key Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Yingyi Guo *Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yingzhuo LinKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Xiaohu WangKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Guohua HeKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Mingzhen WangKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Jianbo XuKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Mingdong SongKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Xixi TanKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Chao ZhuoGuangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhiwei LinKey Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftazidime-avibactam (CZA) is one of the effective antibiotics used for the treatment of carbapenem-resistant

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeCeftazidimeDrug CombinationsKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsBacterial ProteinsCarbapenemsChinaDrug Resistance, Multiple, BacterialHumansWhole Genome SequencingAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCarbapenemsCeftazidimeDrug Combinationscarbapenem-resistant Klebsiella pneumoniaeceftazidime-avibactamexpression of KPCheteroresistanceinhibition strategy

Identifiers

PMID39711783
PMCPMC11659205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.